SOURCE: TomoTherapy


February 10, 2011 06:00 ET

University Clinic Heidelberg Introduces New TomoTherapy® TomoHD™ Radiation Therapy System

Patient Treatments Commence on Germany's First TomoHD System

MADISON, WI--(Marketwire - February 10, 2011) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for the treatment of cancer and other diseases, today announced that University Clinic Heidelberg, one of the top radiation oncology institutes in the world, is expanding its cancer treatment capabilities with the introduction of the TomoHD radiation therapy system. This is the first TomoHD system to be installed in Germany. Patient treatments commenced on February 3, 2011.

In March 2006, University Clinic Heidelberg became the first facility in Germany to offer helical image-guided, intensity-modulated radiation therapy (IG-IMRT) using TomoTherapy's Hi·Art® treatment system. The addition of the TomoHD radiation therapy system almost five years later will provide clinicians more flexibility to treat a broader patient population.

By combining TomoHelical and TomoDirect delivery modes, the TomoHD treatment system is a multi-purpose treatment system designed to efficiently target a broad range of cases requiring radiation therapy. The system's TomoHelical technique allows for continuous 360-degree delivery of radiation for complex treatment volumes, while the TomoDirect modality enables clinicians to choose multiple discrete angles for highly efficient treatment of more common targets. In either delivery mode, clinicians will use the same integrated processes they have become accustomed to with the TomoTherapy platform for planning, imaging and treating patients.

"Because we reached capacity with our original TomoTherapy system, we had been reserving this treatment for patients with complex areas of disease who were traveling long distances to seek care. With the addition of our TomoHD system, we can now increase the number of patients who receive advanced cancer care made possible with the use of TomoTherapy technology," said Prof. Dr. Klaus Herfarth, vice chairman at the Department of Radiation Oncology at University of Heidelberg. "We believe the TomoDirect delivery mode, along with forthcoming innovations, will enable us to expand our treatment range and dramatically increase patient throughput."

University Clinic Heidelberg is a research partner of TomoTherapy that continues to study the development of advanced delivery techniques for the TomoHD treatment system platform. 

"University Clinic Heidelberg has been an important partner in the ongoing development of the TomoTherapy platform. We are proud that the clinic has chosen to bring the increased capabilities of the TomoHD system to patients in Germany, and we look forward to further collaboration that will pave the way for even better patient care," said Fred Robertson, M.D., TomoTherapy's president and CEO.

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

Forward-Looking Statements
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms "expected to," "should," "could," "believe(s)," "suggests" or "indicates" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to gain customer acceptance, ability to complete development in a timely manner, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2011 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, Hi·Art, TomoHD and the TomoTherapy logo are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Director, Corporate Communications
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    Email Contact